Kiniksa Pharmaceuticals International, plc
KNSA Nasdaq
SEC CIK 1730430
Follow Kiniksa Pharmaceuticals International
Weekly email: filings, results, news
Revenue, last quarter
$214.3M
+55.5% vs same quarter last year
Net income
$22.6M
+164.6% vs same quarter last year
EPS, diluted
$0.27
+145.5% vs same quarter last year
Operating cash flow
$50.2M
+124.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $677.6M | $59M |
| FY24 | $423.2M | −$43.2M |
| FY23 | $270.3M | $14.1M |
| FY22 | $220.2M | $183.4M |
| FY21 | $38.5M | −$157.9M |
| FY20 | - | −$161.4M |
| FY19 | - | −$161.9M |
| FY18 | - | −$103.2M |
| FY17 | - | −$64.9M |
| FY16 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 88.5% | 11.4% | 8.7% |
| FY24 | 85.6% | −10.8% | −10.2% |
| FY23 | 87.6% | −9.3% | 5.2% |
| FY22 | 89.6% | 4.4% | 83.3% |
| FY21 | 76.4% | −406.4% | −409.7% |
| FY20 | - | - | - |
| FY19 | - | - | - |
| FY18 | - | - | - |
| FY17 | - | - | - |
| FY16 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $136.4M |
| FY24 | $25.4M |
| FY23 | $13.2M |
| FY22 | $5.7M |
| FY21 | −$126.7M |
| FY20 | −$136.8M |
| FY19 | −$161.6M |
| FY18 | −$86.3M |
| FY17 | −$50.3M |
| FY16 | - |
- Kiniksa Pharmaceuticals International
- Healthcare median
Show the numbers
| Year | Kiniksa Pharmaceuticals International | Healthcare median |
|---|---|---|
| FY25 | 8.7% | −40.6% |
| FY24 | −10.2% | −60.7% |
| FY23 | 5.2% | −97.1% |
| FY22 | 83.3% | −128.5% |
| FY21 | −409.7% | −129.2% |
| FY20 | - | −136.5% |
| FY19 | - | −133.7% |
| FY18 | - | −173.4% |
| FY17 | - | −176.7% |
| FY16 | - | −164.8% |
News
No stories filed under Kiniksa Pharmaceuticals International yet - coverage appears here as the news feed clusters it.